TORONTO, Jan. 11, 2018 /CNW/ - Nuuvera Inc. ("Nuuvera")
(TSXV:NUU) is pleased to announce that it has signed a Letter of
Intent ("LOI") with Isodiol International Inc. ("Isodiol")
(CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F), to import 99%+ pure, bioactive
pharma-grade cannabidiol ('CBD') isolate into Canada from Isodiol's GMP-certified production
facility in the United Kingdom.
The product, certified as a pharmaceutical-grade, will be
imported into Canada through
Nuuvera's subsidiary, ARA - Avanti Rx Analytics Inc. ("Avanti"), a
Health Canada GMP-certified laboratory holding a dealer license
under the Narcotic Control Regulations and Office of Controlled
Substances.
"As one of the first imports into Canada of any cannabis-related product, this
signifies a tremendously exciting breakthrough," explained
Lorne Abony, Chief Executive Officer
of Nuuvera. "This agreement marks a meaningful step in Nuuvera's
strategy to utilize its extensive international operational and
production base to develop the highest quality products in the
world, and serve emerging markets in the cannabis industry," said
Abony.
Nuuvera intends to import up to 30,000 kg of CBD isolate per
month for the purposes of R&D, product formulation and
production of pharma-grade derivative products. Through its
licensed subsidiaries, Nuuvera aims to sell these products in
Canada and export to licensed
international medical cannabis jurisdictions.
Marcos Agramont, CEO of ISO
International Inc., stated, "Since establishing Isodiol we have
focused on developing and marketing the highest quality, raw
material for use in a range of proprietary, pharma grade
nutritional and health related remedies. I am pleased that our new
partner, Nuuvera, which brings to the table extensive knowledge and
expertise in the fields of quality control, R&D, and product
development shares Isodiol's vision for an industry built upon
quality, consistency, safety, and ultimately, efficacy."
Upon successful initial import and product testing, Nuuvera and
Isodiol intend to execute a Definitive Supply Agreement, the terms
of which are already substantively agreed upon. The activities
contemplated by the LOI remain subject to applicable regulatory
approvals, including those from Health Canada, and the TSX Venture
Exchange.
For more information on Nuuvera, please visit:
www.nuuvera.com
About Nuuvera
Nuuvera is a global cannabis company
founded on Canadian principles, and built with the whole world in
mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in
several other countries, to develop commercial production and
global distribution of medical grade cannabis in legalized markets.
Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon
Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the
Narcotic Control Regulations and Office of Controlled Substances.
Nuuvera is currently in the final stages of the Health Canada
review process to become a Licensed Producer of medical marijuana
under the ACMPR, and has recently received its "letter to build"
approval.
About Isodiol International Inc.
Isodial International
Inc. is the market leader in pharmaceutical grade phytochemical
compounds and the industry leader in the manufacturing and
development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry
including commercialization of 99%+ pure, bioactive pharmaceutical
grade cannabinoids, micro-encapsulations, and nanotechnology for
the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of
over-the-counter and pharmaceutical drugs, expanding its
phytoceutical portfolio and will aggressively continue
international expansion into Latin
America, Asia and
Europe.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
Nuuvera and its business. Often, but not always, forward-looking
statements can be identified by the use of words such as "plans",
"is expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would", "might"
or "will" be taken, occur or be achieved. Such statements are based
on the current expectations of the management of Nuuvera. The
forward-looking events and circumstances discussed in this release
may not occur by certain specified dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Nuuvera, including risks regarding the
cannabis industry, failure to obtain regulatory approvals, economic
factors, the equity markets generally and risks associated with
growth and competition. Although Nuuvera has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made Nuuvera undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
The TSX Venture Exchange has in no way passed upon the merits
of the transaction and has neither approved nor disapproved the
content of this press release.
SOURCE Nuuvera Inc.